国际新闻精选周五（2017年1月6日）

Halozyme jumps, then lands, on positive late-stage pancreatic cancer data

Halozyme saw its shares boosted by nearly 60% premarket on news that it had hit its endpoints in a midstage test of its candidate in the notoriously difficult-to-treat pancreatic cancer therapy area, but its shares rally did not last long.【阅读原文】

Top 10 pipeline blowups, setbacks and snafus in H2 2016

2016 has to rank as one of the most disastrous years in recent drug R&D history. We’ve been treated to everything from a repeat Phase III debacle for Eli Lilly in Alzheimer’s to back-to-back clinical holds on a CAR-T drug that kills patients from Juno. We’ve seen stellar organizations like Bristol-Myers’ R&D team overstep while Gilead went from doing no wrong to doing no right.【阅读原文】

Another Langer-backed biotech breaks out of stealth mode, aims for the clinic with hearing loss therapy

Over the last 18 months the team at Frequency Therapeutics’ Kendall Square office has been making quiet progress with its preclinical work on a new approach to curing hearing loss, exploring the potential of a therapeutic technique that emerged out of the lab of MIT’s serial science entrepreneur Bob Langer and his colleague Jeff Karp. Today, though, the stealthy ramp-up is over as the biotech debuts its management team and R&D strategy.【阅读原文】

Could Amgen's Patent Victory Be Bad For Medicine?

Last night, in a nearly unprecedented move, a federal judge ordered a cholesterol medicine that is on the market and used by patients to be withdrawn because it infringes on the patents of a competitor. Some patent attorneys reacted with shock. “It’s very strange for a judge to take one product off the market when there are patients on the medicine already,” says Rachel Sachs, an associate professor of law at Washington University in St. Louis. In an extended thread on Twitter about the decision, New York Law School Associate Professor Jacob Sherkow wrote: “I am shocked.”【阅读原文】

★ 请关注《美中药源》微信公众号 ★